Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease
Authors:
- Noel S. WeissNWNoel S. Weiss
- Curt D. FurbergCFCurt D. Furberg
- Thomas D. KoepsellTKThomas D. Koepsell
- David S. SiscovickDSDavid S. Siscovick
- Frits R. RosendaalFRFrits R. Rosendaal
- Nicholas L. SmithNSNicholas L. Smith
- Susan R. HeckbertSHSusan R. Heckbert
- Robert C. KaplanRKRobert C. Kaplan
- Danyu LinDLDanyu Lin
- Thomas R. FlemingTFThomas R. Fleming
- Edward H. WagnerEWEdward H. Wagner
- 25 August 1999
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 282 (8) , 786-790
Abstract
Data on surrogate end points such as blood pressure or body weight have often been used to support the approval of new pharmacologic treatments for cardiovascKeywords
This publication has 20 references indexed in Scilit:
- Does Hyperglycemia Really Cause Coronary Heart Disease?Diabetes Care, 1997
- Valvular Heart Disease Associated with Fenfluramine–PhentermineNew England Journal of Medicine, 1997
- Surrogates, Semantics, and Sensible Public PolicyCirculation, 1997
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Appetite-Suppressant Drugs and the Risk of Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes MellitusAnnals of Internal Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Research and Clinical Practice, 1995
- Cholesterol Reduction Yields Clinical BenefitCirculation, 1995
- Role of surrogate end points in the evaluation of drugs for heart failureJACC, 1993